Contact

All Stories

  1. Intestinally Active Therapies for Hypercholesterolemia: Ezetimibe, Bile Acid Resins, and Plant Sterols

    Article • December 2020, Springer Science + Business Media

    Dr Thomas D Dayspring

  2. Sterol biomarkers were evaluated in 667,718 patient blood samples

    Article • Journal of Clinical Lipidology, November 2015, Elsevier

    Dr Thomas D Dayspring

  3. Lipid and Lipoproteins Metrics in Women

    Article • Clinical Lipidology, October 2015, Future Medicine

    Dr Thomas D Dayspring

  4. Does APOE Genotype Modify the Relations Between Serum Lipid and Erythrocyte Omega-3 Fatty Acid Levels?

    Article • Journal of Cardiovascular Translational Research, March 2014, Springer Science + Business Media

    Dr Thomas D Dayspring

  5. Omega-3 Fatty Acids and Cardiovascular Disease: New Developments and Applications

    Article • Postgraduate Medicine, November 2013, Taylor & Francis

    Dr Thomas D Dayspring

  6. Apoproteins and Cell Surface Receptors Regulating Lipoprotein Metabolism in the Setting of Type 2 Diabetes

    Article • July 2013, Springer Science + Business Media

    Dr Thomas D Dayspring

  7. Oral Contraceptives: A Cause of Elevated LDL-Particle Number in Two Young Dyslipidemic Women*

    Article • Journal of Clinical Lipidology, May 2013, Elsevier

    Dr Thomas D Dayspring

  8. High Proportion of Discordance between ApoB and LDL-P in Clinical Practice is Associated with Insulin Resistance in More than 80,000 Individuals

    Article • Journal of Clinical Lipidology, May 2013, Elsevier

    Dr Thomas D Dayspring

  9. Pseudohypertriglyceridemia - verifying the hypertriglyceridemic patient

    Article • Journal of Clinical Lipidology, March 2013, Elsevier

    Dr Thomas D Dayspring

  10. Pseudohypertriglyceridemia: Two cases of probable glycerol kinase deficiency

    Article • Journal of Clinical Lipidology, September 2012, Elsevier

    Dr Thomas D Dayspring

  11. Evaluation of Low-Density Lipoprotein Particle Number Distribution in Patients With Type 2 Diabetes Mellitus With Low-Density Lipoprotein Cholesterol <50 mg/dl and Non-High-Density Lipoprotein Cholesterol <80 mg/dl

    Article • The American Journal of Cardiology, September 2012, Elsevier

    Dr Thomas D Dayspring, Dr Ray Pourfarzib

  12. Ezetimibe therapy: mechanism of action and clinical update

    Article • Vascular Health and Risk Management, July 2012, Taylor & Francis

    Dr Thomas D Dayspring

  13. Drug safety evaluation of rosuvastatin

    Article • Expert Opinion on Drug Safety, October 2011, Informa Healthcare

    Dr Thomas D Dayspring

  14. Effects of Fenofibric Acid in Combination with Statin Therapy on LDL and HDL Particle Number in Patients with Mixed Dyslipidemia †

    Article • Journal of Clinical Lipidology, May 2011, Elsevier

    Dr Thomas D Dayspring

  15. Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters

    Article • International Journal of Women s Health, March 2011, Taylor & Francis

    Dr Thomas D Dayspring

  16. Moving beyond LDL-C: incorporating lipoprotein particle numbers and geometric parameters to improve clinical outcomes

    Article • Research Reports in Clinical Cardiology, November 2010, Taylor & Francis

    Dr Thomas D Dayspring

  17. Impact of triglycerides on lipid and lipoprotein biology in women

    Article • Gender Medicine, June 2010, Elsevier

    Dr Thomas D Dayspring

  18. Images, lipoproteins, drugs, and atherothrombotic events

    Article • Menopause, July 2009, Wolters Kluwer Health

    Dr Thomas D Dayspring

  19. Drug therapy for hypertriglyceridemia: Fibrates and omega-3 fatty acids

    Article • Current Atherosclerosis Reports, December 2008, Springer Science + Business Media

    Dr Thomas D Dayspring

  20. 215: Effects of ABT-335 in Combination with Rosuvastatin on Low-Density Lipoprotein Particle Size in Patients with Mixed Dyslipidemia

    Article • Journal of Clinical Lipidology, June 2008, Elsevier

    Dr Thomas D Dayspring

  21. Pharmacotherapeutic decisions in menopausal women with cardiovascular risk

    Article • Future Lipidology, April 2007, Future Medicine

    Dr Thomas D Dayspring

  22. High‐Density Lipoproteins: Emerging Knowledge

    Article • Journal of the CardioMetabolic Syndrome, January 2007, Wiley

    Dr Thomas D Dayspring

  23. Fibrate therapy in patients with metabolic syndrome and diabetes mellitus

    Article • Current Atherosclerosis Reports, September 2006, Springer Science + Business Media

    Dr Thomas D Dayspring

  24. Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia

    Article • Metabolism, July 2006, Elsevier

    Dr Thomas D Dayspring

  25. National Lipid Association: Annual Scientific Sessions

    Article • Future Lipidology, February 2006, Future Medicine

    Dr Thomas D Dayspring

  26. 1047-186 Raloxifene improves lipoprotein, apolipoprotein and fibrinogen in postmenopausal osteoporotic women with or without hypertriglyceridemia

    Article • Journal of the American College of Cardiology, March 2004, Elsevier

    Dr Thomas D Dayspring

  27. Seeing the forest through the trees: big trucks—little trucks

    Article • Menopause, March 2002, Wolters Kluwer Health

    Dr Thomas D Dayspring

  28. Prevention of a First Myocardial Infarction

    Article • The Journal of Clinical Pharmacology, April 2001, Wiley

    Dr Thomas D Dayspring

  29. Estrogen and atherothrombosis editorial 2 1Letters (from the United States) concerning a particular article in The American Journal of Cardiology must be received within 2 months of the article's publication, and should be limited (with rare exceptions...

    Article • The American Journal of Cardiology, August 2000, Elsevier

    Dr Thomas D Dayspring